CSF lactate for accurate diagnosis of community-acquired bacterial meningitis.

CSF lactate measurement is recommended when nosocomial meningitis is suspected, but its value in community-acquired bacterial meningitis is controversial. We evaluated the diagnostic performance of lactate and other CSF parameters in a prospective cohort of adult patients with acute meningitis. Diagnostic accuracy of lactate and other CSF parameters in patients with microbiologically documented episodes was assessed by receiver operating characteristic (ROC) curves. The cut-offs with the best diagnostic performance were determined. Forty-five of 61 patients (74%) had a documented bacterial (n = 18; S. pneumoniae, 11; N. meningitidis, 5; other, 2) or viral (n = 27 enterovirus, 21; VZV, 3; other, 3) etiology. CSF parameters were significantly different in bacterial vs. viral meningitis, respectively (p < 0.001 for all comparisons): white cell count (median 1333 vs. 143/mm(3)), proteins (median 4115 vs. 829 mg/l), CSF/blood glucose ratio (median 0.1 vs. 0.52), lactate (median 13 vs. 2.3 mmol/l). ROC curve analysis showed that CSF lactate had the highest accuracy for discriminating bacterial from viral meningitis, with a cutoff set at 3.5 mmol/l providing 100% sensitivity, specificity, PPV, NPV, and efficiency. CSF lactate had the best accuracy for discriminating bacterial from viral meningitis and should be included in the initial diagnostic workup of this condition.

Le stress chez l'aidant naturel dont le proche est en traitement initial d'un cancer du poumon

Le cancer du poumon fait partie des cancers les plus fréquents. Diagnostiqué à un stade souvent tardif, il se caractérise par un mauvais pronostic et de lourdes répercussions sur la santé du patient. La phase de traitement initial représente un moment critique où les proches du patient deviennent aidants naturels du patient et endossent de nouvelles responsabilités. Cette situation génère des conséquences en termes de stress chez l'aidant naturel. Le but de cette étude était de décrire l'importance du stress chez l'aidant naturel du patient en traitement initial pour un cancer du poumon. L'approche méthodologique utilisée est de type descriptif transversal. L'échantillon de convenance était composé de 28 aidants naturels et 26 patients en traitement initial pour un cancer du poumon suivis dans un centre d'oncologie ambulatoire universitaire en Suisse. L'importance du stress des aidants naturels a été évaluée à partir de l'instrument Caregiver Reaction Assessment (CRA) de Given et al. (1992) complété d'une question mesurant la perception du manque d'information. Le CRA mesure le ressenti de l'aidant naturel face aux dimensions négatives et positive du stress sur une échelle de type Likert à cinq points. Le modèle des systèmes de Neuman (2002) a servi de cadre théorique à l'étude. Les aidants naturels ont accordé une importance plus élevée (score moyen 4,15) à l'Estime de soi, dimension positive du stress qu'aux dimensions négatives. Parmi celles-ci, la Perturbation des activités représente la dimension qui affecte le plus le quotidien des aidants (score moyen 2,96). Les caractéristiques sociodémographiques de l'aidant et les données médicales du patient, semblent avoir une influence sur l'importance du stress perçu, mais d'autres marqueurs objectifs doivent être identifiés pour affiner l'interprétation de ces relations. Une grande majorité (78%) des aidants ont indiqué qu'ils disposaient d'assez d'information pour soigner, indiquant que l'information est un sujet important dans leur vécu et mérite une évaluation plus poussée en tant que dimension du stress associé au rôle d'aidant naturel. L'infirmière doit viser par ses actions à préserver l'intégrité et la stabilité de la santé de l'aidant naturel comme elle le fait pour les patients. L'investigation systématique du stress représente une intervention prioritaire chez les aidants naturels dans le contexte oncologique. Des interventions personnalisées pourront être ainsi développées, afin de soutenir l'aidant naturel dans ses activités d'aide auprès de son proche tout en préservant sa propre santé.

Prognostic value of PCSK9 levels in patients with acute coronary syndromes.

AIMS: Proprotein convertase subtilisin kexin 9 (PCSK9) is an emerging target for the treatment of hypercholesterolaemia, but the clinical utility of PCSK9 levels to guide treatment is unknown. We aimed to prospectively assess the prognostic value of plasma PCSK9 levels in patients with acute coronary syndromes (ACS). METHODS AND RESULTS: Plasma PCSK9 levels were measured in 2030 ACS patients undergoing coronary angiography in a Swiss prospective cohort. At 1 year, the association between PCSK9 tertiles and all-cause death was assessed adjusting for the Global Registry of Acute Coronary Events (GRACE) variables, as well as the achievement of LDL cholesterol targets of <1.8 mmol/L. Patients with higher PCSK9 levels at angiography were more likely to have clinical familial hypercholesterolaemia (rate ratio, RR 1.21, 95% confidence interval, CI 1.09-1.53), be treated with lipid-lowering therapy (RR 1.46, 95% CI 1.30-1.63), present with longer time interval of chest pain (RR 1.29, 95% CI 1.09-1.53) and higher C-reactive protein levels (RR 1.22, 95% CI 1.16-1.30). PCSK9 increased 12-24 h after ACS (374 ± 149 vs. 323 ± 134 ng/mL, P < 0.001). At 1 year follow-up, HRs for upper vs. lower PCSK9-level tertiles were 1.13 (95% CI 0.69-1.85) for all-cause death and remained similar after adjustment for the GRACE score. Patients with higher PCSK9 levels were less likely to reach the recommended LDL cholesterol targets (RR 0.81, 95% CI 0.66-0.99). CONCLUSION: In ACS patients, high initial PCSK9 plasma levels were associated with inflammation in the acute phase and hypercholesterolaemia, but did not predict mortality at 1 year.

Care delivery value chains for ophthalmic clinics in Switzerland

Perceived patient value is often not aligned with the emerging expenses for health care services. In other words, the costs are often supposed as rising faster than the actual value for the patients. This fact is causing major concerns to governments, health plans, and individuals. Attempts to solve the problem have habitually been on the operational effectiveness side: increasing patient volume, minimizing costs, rationing, or closing hospitals, usually resulting in a zero-sum game. Only few approaches come from the strategic positioning side and "competition" among hospitals is still perceived rather as a danger than as a chance to create a positive-sum game and stimulate patient value. In their 2006 book, "Redefining Health Care", the renowned Harvard strategy professor Michael E. Porter and hospital management expert Professor Elizabeth Olmsted Teisberg approach the challenge from the positive-sum perspective: they propose to form Integrated Practice Units (IPUs) and manage hospitals in a modern, patient value oriented way. They argue that creating value-based competition on results should have the same effect on the health care sector like transparency and competition turned other industries with out-dated management models (like recently the inert telecommunication industry) into highly competitive and customer value creating businesses. The objective of this paper is to elaborate Care Delivery Value Chains for Integrated Practice Units in ophthalmic clinics and gather a first feedback from Swiss hospital managers, ophthalmologists, and patients, if such an approach could be a realistic way to improve health care management. First, Porter's definition of competitiveness (distinction between operational effectiveness and strategic positioning) is explained. Then, the Care Delivery Value Chain is introduced as a key element for understanding value-based management, followed by three practice examples for ophthalmic clinics. Finally, recommendations are given how the Care Delivery Value Chain can be managed efficiently and how the obstacles of becoming a patient-oriented organization can be overcome. The conclusion is that increased transparency and value-based competition on results has the potential to change the mindset of hospital managers-which will align patient value with the emerging health care expenses. Early adapters of this management approach will gain a competitive advantage. [Author, p. 6]